The global erythropoietin (EPO) drugs market is set to achieve around USD 17.4 billion by 2025. EPO is a hormone produced by cells in the kidney, which regulates production of red cells in bone marrow. These kidney cells can release EPO when the content of oxygen is very low. EPO instigates the bone marrow to create more red blood cells to increase the oxygen-carrying capacity of blood.
The main function of EPO is to increase oxygen absorption and reduce fatigue. It also helps improve metabolism rate and increase healing capability of muscles. This is possible as the additional red cells transport more oxygen as well as nutrients to the body.
Anemia occurs when there is insufficient hemoglobin present in an individual’s blood. The condition may also occur due to a person’s inability to produce EPO. Patients suffering from HIV, chronic kidney disease (CKD), and cancer are more prone to anemia. So, EPO biosimilars such as epoetin-zeta and epoetin-omega and biologics such as Epoetin-alfa and Epoetin-beta can be used to address anemia in such patients.
Epogen was the first EPO drug approved by the U.S. FDA for treating anemia caused by CKD.
GlaxoSmithKline PLC (GSK) recently launched a phase 3 study on its daprodustat drug. This tablet can be used to treat anemia in patients with chronic kidney disease. This vital oral pill is intended to improve the human body’s response to low levels of oxygen and increase the natural production of EPO in kidneys.
According to Grand View Research, Inc., rising prevalence of chronic diseases such as CKD, HIV, and cancer is expected to raise the demand for EPO drugs. Patent expirations of major biologics are expected to create opportunities for EPO biosimilars. For example, Amgen’s patent for Epogen expired in 2015, opening avenues for other drug manufacturers.
Biosimilars are inexpensive, easy to develop, and require less time for approval compared to biologics. Therefore, the biosimilar segment is expected to boost market growth over the forecast period (2014 to 2025).
By application, renal diseases accounted for the largest share owing to high occurrence of anemia. Cancer is projected to be the fastest growing segment due to high demand for EPO drugs to be used along with cancer chemotherapy. The hematology segment is estimated to observe steady growth during the forecast period due to increasing R&D activities for developing feasible solutions for treating hypoxia and anemia at an initial stage.
In 2016, North America accounted for the largest market share owing to rising prevalence of chronic diseases such as HIV and cancer. The EPO drugs market in Asia Pacific is projected to observe the fastest CAGR owing to high demand for low-cost therapeutics to treat chronic diseases.
Prominent players operating in the market include Johnson & Johnson, Teva Pharmaceutical Industries Ltd, LG Life Sciences Ltd, Dr. Reddy’s Laboratories Ltd, and Sun Pharmaceutical Industries Ltd.
In-Depth research report on Erythropoietin (EPO) Drugs Market: http://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market
No comments:
Post a Comment